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Abstract
The devastating malaria, caused by parasites of the genus Plasmodium, afflicts nearly half 
of the world's population and imposes a heavy socio‐economic burden particularly to the 
disease‐endemic Sub‐Saharan Africa. Sustained efforts in malaria control have been made 
from the perspectives of medicine‐ and vaccine‐based prevention and treatment of malaria 
and malaria transmission blockage for the past 15 years, resulting in a decreased mor‐
tality rate by 60% and a decreased malaria incidence rate by 37% globally. Nonetheless, 
due to the emergence and rapid spread of drug‐resistant parasite strains, novel antima‐
larial drugs are urgently required to combat this deadly disease. Plasmepsins are deemed 
potential targets for novel antimalarial drug design. Plasmepsins represent an aspartic 
proteinase family that can be sub‐categorized into seven groups based on the amino acid 
sequence identity. This chapter discusses our progress in understanding the biosynthesis, 
biological functions and enzymatic characteristics of the plasmepsin family. This led to 
development of various types of plasmepsin‐targeted compounds and the assessment of 
their binding affinity and selectivity, anti‐parasitic activity and cytotoxicity. The gained 
experience and current status in developing plasmepsin‐targeted antimalarial drugs are 
addressed. Finally, a deeper and broader investigation on the functions and characteristics 
of the plasmepsin family is encouraged.
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1. Introduction
Malaria, a life‐threatening infectious disease, afflicts approximately 3.2 billion people, causes 
214 million clinical cases and leads to nearly 440,000 deaths worldwide in 2015 despite the facts 
that malaria mortality rates decreased by 60% globally and by 66% in Africa between 2000 and 
2015, and that malaria incidence rates decreased by 37% globally and by 42% in Africa for the 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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past 15 years [1, 2]. Nearly 90% of the malaria cases and deaths occur in Sub‐Saharan Africa in 
2015, loading a heavy socio‐economic burden to this poorly developed region [1].
Malaria is caused by parasitic protozoa of the genus Plasmodium. Hundreds of Plasmodium 
species have been identified to infect reptiles, birds and mammals, including rodents and 
primates. Four Plasmodium species pluralis (spp.), P. falciparum, P. vivax, P. malariae and P. ovale, 
are known to infect man, though other malarial species of non‐human primates occasionally 
infect human as well. Among these species, P. falciparum is the most deadly and P. vivax, 
the most prevalent. P. falciparum invades both young and mature erythrocytes and provokes 
malignant disease symptoms. Prevalent mainly in Africa, P. falciparum accounts for ~40% of 
the clinical cases on a global basis [1]. In contrast, P. vivax prefers invading young erythrocytes 
and causes benign symptoms; it has a wider geographical distribution than P. falciparum and 
is responsible for half of the total reported cases [1].
To complete its life cycle, the malaria parasite requires a female mosquito as the transmission 
vector and a vertebrate host (Figure 1). When a blood meal is taken, a parasite‐infected mos‐
quito inoculates sporozoites into the human host to start the exo‐erythrocytic phase, in which 
sporozoites infect hepatocytes and mature into schizonts. Of note, in parasites such as P. vivax 
and P. ovale, a dormant stage, namely hypnozoites, can maintain in hypatic cells for weeks or 
even years before invading the bloodstream. Rupture of schizonts releases merozoites, which 
Figure 1. The life cycle of malaria parasites. Malaria parasites require a transmission vector (e.g., mosquito) and a 
vertebrate host (e.g., human) to complete their life cycle. The exo‐erythrocytic and intra‐erythrocytic phases occur in the 
vertebrate host, and the sporogonic phase occurs in the transmission vector.
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then infect erythrocytes to initiate the intra‐erythrocytic phase. In this phase, the parasite 
undergoes multiple rounds of asexual replication with each cycle comprising, in sequence, 
the ring, the trophozoite and the schizont stage. A portion of merozoites infect erythrocyte 
to differentiate into gametocytes. Microgametocytes and macrogametocytes are ingested by 
a mosquito to start the sporogonic phase. In the mosquito's stomach, gametocytes further 
differentiate into gametes. Microgametes fertilize macrogametes to generate zygotes, which 
subsequently develop into motile and elongated ookinetes. Ookinetes penetrate the midgut 
of the mosquito and develop into oocysts, from which sporozoites are released and delivered 
to the mosquito's salivary gland, ready for the next infection.
Malaria control in the modern era arguably starts from the isolation of antimalarial quinine 
and quinidine from cinchona bark in early nineteenth century [3], while it was not until 1925 
that pamaquine (also known as plasmoquine or plasmochin), the first synthetic antimalarial 
drug, was yielded. Synthesized in 1934, chloroquine (CQ), a 4‐aminoquinoline compound, 
exhibited a strong antimalarial potency and a low toxicity and became the most extensively 
used drug in malaria prophylaxis and treatment between 1940s and 1960s [4–6]. The massive 
use of CQ, however, resulted in the emergence of CQ‐resistant P. falciparum strains, which 
promoted development of novel antimalarial drugs (e.g., 8‐aminoquinolines, antifolates, 
naphthoquinones and non‐antifolate antibiotics). Of particular note among these compounds 
is artemisinin (AN). Extracted from the herbal plant Artemisia annua, AN, has been used for 
malaria treatment since early 1970s [7]. Though AN and its various derivatives display high 
antimalarial activities (e.g., [8–12]) and quick attenuation of disease symptoms [13], they have 
short half lives in vivo [14]. The combination of AN and a longer‐acting drug (e.g., artemether‐
lumefantrine and artesunate‐mefloquine) is effective for disease treatment and for defer‐
ring drug resistance development. Artemisinin‐based combination therapies (ACTs) have 
up till now been used as a standard therapy in many countries and regions despite poten‐
tially unmatched pharmacokinetics between drugs and/or widespread resistance against the 
non‐artemisinin components. Malaria control was also carried out by intervention of disease 
transmission, thanks to the discovery of insecticidal properties of dichloro‐diphenyltrichlo‐
roethane (DDT) in 1939 [15]. Due to health and environmental risks, DDT was later substi‐
tuted by other insecticides, such as pyrethroids, chlorfenapyr and pyriproxyfen. While both 
indoor residual spraying and insecticide‐treated bed nets contribute to controlling epidemic 
outbreaks of malaria, the latter provide more effective protection for people living in tempo‐
rary shelters. Nonetheless, one cannot ignore the growing emergence of insecticide‐resistant 
vector strains and the lack of interventions targeting outdoor mosquito populations, which 
constitute major challenges in blocking malaria transmission. Intervention of malaria trans‐
mission has also been managed via biological control of mosquitoes at both the larval and the 
adult stage. Several fish species, such as Poecilia reticulate (guppy) and Gambusia affinis (mos‐
quitofish), are able to consume mosquito larvae and reduce their population; however, these 
fish also pose a threat to other native aquatic predators of mosquitoes due to intraguild preda‐
tion [16, 17]. In contrast, the larval dytiscid beetles Agabus do exhibit a selective predation on 
mosquitoes over alternative prey, although intraguild predation and cannibalism also occur 
within and between Agabus species [18]. In addition, the use of water‐dispersible granular for‐
mulation of two Bacillus species in malaria control results in an efficacious elimination of the 
larval mosquito population with a negligible environmental impact [19]. Also of note is the 
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use of fungi for malaria control. Ground and aerial application of self‐propagating Lagenidium 
giganteum effectively controls the larval mosquito population for at least an entire breeding 
season [20, 21]. Oil‐based formulations of fungal entomopathogens are able to block malaria 
transmission by reducing adult mosquito survival and altering parasite survival/maturation 
in the vector [22]. Further, transgenic fungi Metarhizium anisopliae targeting sporozoites in 
mosquitoes inhibit parasite development [23]. These pieces of evidence indicate the potential 
of fungi as a biocontrol agent of mosquitoes. Natural products are another important source 
utilized to control malaria transmission. A variety of plant extracts and essential oils (e.g., the 
neem oil, the fenugreek oil and the extracts from Indian sandalwood) exhibit larvicidal activi‐
ties and adult mosquito repellency properties (for example, see [24–30]). Moreover, natural 
product‐synthesized silver nanoparticles show a higher potency in mosquitocidal activity 
than the aqueous extracts but their toxicity against other natural mosquito consumers is neg‐
ligible (for example, see [31–33]). These, in addition to the time‐efficiency, cost‐effectiveness 
and eco‐friendliness green‐synthesis of nanoparticles, suggest the feasibility and importance 
of a synergistic mosquito control using botanical nano‐insecticides and biological agents. 
Besides these antimalarial approaches, vaccines against malaria parasites have been under 
development since 1970s [34, 35]. Malaria vaccines are categorized into three types: exo‐
erythrocytic vaccines, blood‐stage vaccines and transmission‐blocking vaccines; sustainable 
prevention requires a combination of vaccines targeting multiple life stages of the parasite. 
RTS,S/AS01, the first and thus far the only vaccine that completes a Phase III clinical trial, 
targets the exo‐erythrocytic phase of P. falciparum. Though this vaccine demonstrates a decent 
efficacy for prevention of clinical malaria cases in African children (age 5–17 months, efficacy 
50%) and infants (age 6–12 weeks, efficacy 30%) [36], an ideal candidate aiming for global 
eradication would require a higher efficacy [37].
A major challenge faced by the anti‐malaria campaign currently is the emergence and rapid 
spread of drug‐resistant variants of Plasmodium spp. [38]. Malaria parasites have developed 
resistance to virtually every type of antimalarial drugs thus far used, including AN and its 
derivatives [39]. The lack of effective treatment of symptoms caused by drug‐resistant para‐
sites urges us to identify molecular targets, against which novel drugs can be subsequently 
developed to combat malaria. Plasmepsins (PMs), a family of aspartic proteinases, are consid‐
ered a promising drug target.
This review focuses on the biosynthesis, biological functions and enzymatic characteristics of 
the plasmepsin (PM) family from human malaria parasites. The progression of PM‐targeted 
antimalarial drug development is also discussed.
2. Plasmepsin family overview
From comparative genomic analysis of sequence information of seven Plasmodium spp. depos‐
ited in the Plasmodium genome database [40], a cohort of genes that encode PMs were iden‐
tified and categorized into seven groups based on their amino acid sequence identity [41]. 
In P. falciparum, up to ten PMs have thus far been identified, namely PfPMs 1, 2, 4–10 and 
PfHAP (Histo‐Aspartic Proteinase) [42]. These PMs, encoded by genes located in five  different 
 chromosomes, are composed of the pro‐segment and the mature enzyme domain. PfPM5 and 
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PfPM9 also contain extra residues at their C‐termini. PMs are distinct in structural and bio‐
chemical properties, such as molecular weight and isoelectric point (Table 1).
Of note, pfpm4, pfpm1, pfpm2 and pfhap cluster in a 20‐kb‐long region of chromosome 14, and 
share a high amino acid sequence identity (Table 1). Each non‐falciparum parasite, however, 
harbors usually one gene (pm4) that shares with pfpm4 the highest sequence identity, which is 
comparable to those shared among the four pfpms. It is believed that the other three PM genes 
may arise from multiple gene duplication events [41]. Since these four PM paralogs were ini‐
tially detected in the food vacuole (FV), an acidic organelle unique to the genus Plasmodium 
where degradation of hemoglobin of red blood cells (erythrocytes) occurs [46–48], they are 
named the FV PfPMs. PM4s of the non‐falciparum species are also grouped as FV PMs because 
they are highly homologous to the FV PfPMs. PfPMs 5–10 share a low amino acid sequence 
identity with the FV PfPMs, and their sequence structures are distinct from each other and 
from those of the FV PfPMs (Table 1), indicating that there exist diverse biological functions 
and enzymatic features among the PM family members.
3. Biosynthesis
3.1. Food vacuole plasmepsins
FV PfPMs are synthesized as type II integral membrane proteins, with the putative trans‐
membrane motif residing in the N‐terminal pro‐segment. Using immunoelectron microscopy 
(immunoEM), PfPM1 and PfPM2 were observed in the lumens of transport vesicles and FVs, 
PM Chr. Pro Zymogen Mature enzyme
# a.a. # a.a. % i.d. MW (Da) pI # a.a. % i.d. MW (Da) pI
PM1 14 123 452 62 51,461 7.23 329 70 37,050 4.82
PM2 14 124 453 61 51,481 5.29 329 69 36,915 4.62
HAP 14 123 451 52 51,694 8.23 328 59 36,979 4.97
PM4 14 121 449 — 51,047 5.19 328 — 36,955 4.38
PM5 13 83 590 25 68,481 7.66 440 25 50,844 6.50
PM6 3 84 432 29 49,434 7.75 348 29 39,352 6.44
PM7 10 76 450 28 52,329 8.44 374 28 43,317 6.09
PM8 14 45 385 26 44,255 9.38 340 29 38,976 8.85
PM9 14 212 627 27 74,184 9.63 402 25 46,970 9.28
PM10 8 232 573 30 65,115 5.22 341 29 38,604 5.38
The % i.d. data is calculated using the Basic Local Alignment Search Tool [43].  The MW and pI data of zymogens are 
adopted from the Plasmodium Genomics Resource [44].  The MW and pI data of mature enzymes are calculated using 
ProtParam [45].  Abbreviations: Pro, pro‐segment; # a.a., numbers of amino acids; % i.d., percentage of identity versus 
PM4.
Table 1. Comparative properties of plasmepsins from the P. falciparum 3D7 strain.
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in the parasite plasma membrane (PPM), in small vesicular structures near PPM and in the 
cytostome, a morphologically variable microstructure comprising invaginated parasitopho‐
rous vacuolar membrane (PVM) and PPM [46] (Figure 2). Further, Klemba and colleagues 
probed the trafficking of PfPM2 in a transgenic P. falciparum culture model [49]. The PfM2‐
green fluorescence protein (GFP) fusion protein was detected by immunoEM in the mem‐
brane and lumen of FVs and in the cytostomes, consistent with the previous finding [46]. 
Administration of brefeldin A (BFA), an inhibitor blocking anterograde protein traffic from 
the endoplasmic reticulum (ER), to trophozoites retained PfPM2‐GFP in the ER/nuclear enve‐
lope (NE); yet this protein was detected in the cytostomes and subsequently the FVs min‐
utes after release of the BFA inhibition. The role of Golgi apparatus in the biosynthesis of FV 
PfPMs is not yet clear, but is doubtful, since FV PfPMs are known to be unglycosylated. Taken 
together, these findings suggest that the biosynthesis of FV PfPMs follows an “ER‐to‐PPM‐
to‐FV” route (Figure 2). Interestingly, PfPM2 has also been detected in the cytoplasm of host 
erythrocytes (see Section 4.2 for more discussion), leading to the hypothesis that there exists 
an alternative traffic route for the FV PMs.
To gain catalytic activity, FV PMs need to release their pro‐segments. The cleavage site is 
conserved at the motif (Y/H)LG* (S/N)XXD (* represents the scissile bond) [50], which is dif‐
ferent from the sites where in vitro PM auto‐maturation occurs ([48, 51–54], see also discussion 
Figure 2. Biosynthesis of plasmepsins in the P. falciparum intra‐erythrocytic phase. Food vacuole plasmepsins from 
P. falciparum (FV PfPMs) are expressed as type II integral membrane proteins with their N‐terminal pro‐segments 
(orange threads) spanning the endoplasmic reticulum/nuclear envelope (ER/NE) membrane. FV PfPMs are transported 
via small vesicular structures to the parasite plasma membrane (PPM), where some reside in the cytostomal vacuole. 
The involvement of Golgi apparatus in this secretory pathway is not clear. Endocytosis of cytostomes retains FV PfPMs 
in transport vesicles, which convey the enzymes eventually to the FV. Maturation of the FV PfPMs is carried out in 
the acidic FVs and transport vesicles. Certain FV PfPMs (e.g., PfPM2) are also found functionally active in the host 
erythrocytes, though how they are secreted outside the parasite is not yet clear. In contrast, PfPM5 is an ER‐resident, type 
I integral membrane protein. PV, parasitophorous vacuole; PVM, parasitophorous vacuolar membrane.
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in Section 5). This observation suggests that PM maturation in the parasite is a convertase‐
catalyzed trans‐processing event. Further studies showed that the pro‐segment cleavage of 
naturally‐occurring PMs occurs in an acidic milieu, is largely completed within half an hour in 
cultured P. falciparum at the trophozoite stage, and is inhibited by tripeptide aldehyde N‐ace‐
tyl‐Leu‐Leu‐norleucinal (ALLN) or N‐acetyl‐Leu‐Leu‐methioninal [50, 55]. The identity of the 
convertase is believed to be the cysteine proteinases falcipain (FP) ‐2 and ‐3 in that (1) both FP‐2 
and FP‐3 catalyze cleavage of peptide substrates at the C‐terminus of the conserved glycine; 
(2) a membrane‐permeant derivative of the cysteine proteinase inhibitor E‐64 directly binds to 
FP‐2 and FP‐3 and, in turn, slows the kinetics of PM maturation in cultured parasites; and (3) 
both FPs are inhibited by ALLN at low micromolar magnitude in vitro [56]. Of note, when FPs 
are inhibited, the parasite can use PMs (e.g. PfPM2) as alternative convertases [56], though it is 
not known yet whether and to what degree this alternative processing is employed.
Where does the maturation of FV PMs occur? Evidence from immunoEM shows that antibod‐
ies directed against N‐terminal epitopes of mature PfPM1 and PfPM2 recognize the enzymes 
not only in the FV but also in transport vesicles [46, 49]. Of note, hemozoin crystals stemmed 
from hemoglobin degradation that is initiated and carried out by mature FV PMs are also 
observed in both the FVs and transport vesicles [57]. These findings indicate that both subcel‐
lular compartments contain catalytically active PMs. In addition, the finding that functional 
vacuolar proton pumps are present in the PPM [58, 59], the outer membrane of transport 
vesicles, suggests that the vesicular milieu is acidic. Taken together, it is conceivable that the 
convertase‐catalyzed PM maturation also occurs in transport vesicles.
The four FV PfPMs exhibit distinct temporal expression patterns in the intra‐erythrocytic phase 
of the parasite life cycle: PfPM1 and PfPM2 emerge as early as the ring stage, PfPM4 first appears 
in the early trophozoite stage, and yet PfHAP is not detected until the mid‐trophozoite stage; all 
the four continue to be expressed at the schizont stage [48]. This is expected since the FV PfPMs 
are key enzymes to hemoglobin processing, and PfPM1 and PfPM2 are believed to initiate that 
event (for more discussion, see Section 4.1). Importantly, expression of these FV PfPMs is not 
restricted in trophozoites and schizonts in that mass spectrometry (MS)‐based analyses have 
identified their presence in gametocytes, merozoites, oocysts and sporozoites [60–62].
No studies, to the author's knowledge, have been reported on biosynthesis of the FV PMs 
from non‐falciparum species. It is likely that they adopt a similar pattern as the PfPMs due to 
the high sequence identity shared among these homologs.
3.2. Non-food vacuole plasmepsins
Among the non‐FV PMs, PM5 is the most studied. PfPM5 is synthesized as a type I integral 
membrane protein comprising an N‐terminal pro‐segment, a catalytic domain, a C‐terminal 
transmembrane domain and a cytoplasmic tail [63]. Notably, the sequence of the pro‐segment 
region of PM5 is highly variable among Plasmodium spp. [44]. PfPM5 is almost exclusively 
detected in the ER/NE (Figure 2) [63]. The C‐terminal transmembrane domain is essential to 
the ER/NE residence of PfPM5 [64]. Expression of PfPM5 is detected throughout the life cycle 
of the parasite [44, 65, 66]; in the intra‐erythrocytic phase, PfPM5 expression starts at the early 
ring stage in a scarce level and continues to increase steadily through the trophozoite and 
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schizont stages, which mirrors the temporal expression patterns of PfPM1 and PfPM2 [48, 63]. 
Interestingly, in contrast to the rapid maturation of the FV PfPMs, no processing of the N‐ter‐
minal pro‐segment is observed hours after the synthesis of PfPM5; also unlike the FV PfPMs, 
PfPM5 is catalytically active in the presence of the pro‐segment [63].
Few studies have addressed the biosynthesis of PMs 6–10. Genes encoding PfPM9 and 
PfPM10, but not PfPMs 6–8, are transcribed in parasites infecting erythrocytes [67]. In the 
intra‐erythrocytic phase, PfPM9 and PfPM10 exhibit a diffuse expression pattern throughout 
the cytoplasm, but are excluded from the FV [48]. Of note, MS‐based analysis indicates the 
presence of PfPM9 in sporozoites and the presence of both PfPM6 and PfPM10 in merozoites 
and sporozoites [60–62]. In addition, expression of PfPM7 and PfPM10 is detected in zygotes 
and ookinetes [68, 69].
4. Biological function
4.1. Hemoglobin digestion and degradation
The primary pathological role that FV PMs play is digestion and degradation of the oxy‐
gen‐carrying hemoglobin that constitutes 95% of cytosolic proteins of human red blood cells 
(Figure 3).
In the intra‐erythrocytic phase, hemoglobin digestion and degradation is carried out between 
the ring and the early schizont stage [70, 71]. A vast majority of hemoglobin, at a millimolar 
concentration in erythrocytes, however, is processed within the 6–12‐hour trophozoite stage 
[72], indicative of an enzyme‐catalyzed event. The processing of hemoglobin occurs mainly 
Figure 3. A diagram illustrating the connections of plasmepsins and their known biological functions.
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in FVs; however, it is also carried out in vesicles arising either from micropinocytosis of cyto‐
plasm of host cells or from endocytosis of cytostomes [57].
Early investigations establish that aspartic and cysteine proteinase activities are responsible 
for hemoglobin processing [73–81]. The successful isolation of FV from cultured trophozoites 
renders possible identification of naturally‐occurring hemoglobin‐processing enzymes [82]. 
PfPM1, the first proteinase purified from isolated FVs, exhibits its cleavage specificity at the 
α‐subunit amino acids F33‐L34 (α33‐34) of native hemoglobin [83]. Located in a highly con‐
served region among vertebrate species [84], this peptide bond is essential for maintaining 
the quaternary structure of the hemoglobin tetramer [85]. Breaking the α33‐34 bond unravels 
the molecule and, in turn, leads to additional enzyme cleavages of the α‐ and β‐subunits [47]. 
Sharing a 73% amino acid sequence identity with PfPM1, PfPM2, the second proteinase puri‐
fied from FVs, also cleaves native hemoglobin at α33‐34, though less efficiently than PfPM1 [47]. 
SC‐50083, a selective inhibitor of PfPM1 over PfPM2 by two orders of magnitude [46], blocks a 
majority of native hemoglobin degradation by FV protein extracts [47], indicating that PfPM1 
initiates the proteolysis. Of note, both PfPM1 and PfPM2 can further digest denatured globin 
into smaller peptides [47]. A third FV PM, PfHAP, purified from FVs, cleaves native hemoglo‐
bin even less efficiently than PfPM2 does and yet shows an efficiency in degrading denatured 
globin equivalent to PfPM2 [48]. Similar to PfHAP, PfPM4 of the recombinant form prefers 
degrading denatured globin than native hemoglobin [48]. Other proteolytic enzymes, such as 
the cysteine proteinase falcipains, the metallo‐proteinase falcilysin and aminopeptidases, are 
actively involved in further degrading hemoglobin fragments to oligopeptides and amino acids 
[42, 86]. These findings indicate that hemoglobin digestion and degradation in P. falciparum is 
an ordered process, in which PfPM1 and PfPM2 initiate the cleavage and various proteinases 
are involved in additional processing. Hemoglobin processing in other human malaria para‐
sites may depend on their FV PMs that are homologous to PfPM4.
The purpose of hemoglobin digestion and degradation has been under debate. Some believe 
that malaria parasites consume hemoglobin as a source of nutrients [87–91], which is sup‐
ported by their limited capacity to de novo synthesis [88, 92] or exogenous amino acid uptake 
[93]. Nonetheless, hemoglobin degradation alone seems insufficient to maintain parasite 
metabolism due to its low contents of cysteine, glutamine, glutamic acid and methionine and 
its lack of isoleucine; in addition, hemoglobin‐derived amino acids are found diffused into the 
host cell [89], indicating an excessive amount of hemoglobin being processed. This leads to a 
second hypothesis positing that the parasites degrade hemoglobin to empty space for their 
development and growth [94]. A third hypothesis, supported by an experimental‐based mod‐
eling study, is that hemoglobin degradation is necessary to maintain the osmotic stability of 
infected erythrocytes such that the malaria parasite is able to grow and replicate in integrated 
host cells [95].
4.2. Cytoskeletal protein processing and host cell remodeling
PfPM2 plays a role in remodeling host erythrocytes. In cultured schizonts, PfPM2 was 
observed in the cytoplasm of the host cell in addition to the parasite [96], suggesting its 
 potential  interactions with cytoskeleton proteins. In support of this finding, recombinant 
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PfPM2 exhibits hydrolysis of spectrin, actin and protein 4.1 at near neutral pH conditions 
[96]. In addition, schizont‐expressed, naturally‐occurring PfPM2, but not PfPM1 or falci‐
pains, is enriched in the size exclusion chromatography (SEC) fractions that show pro‐
teolytic activity of the SH3 motif of the cytoskeletal protein spectrin [96], thus supporting 
its host cell remodeling role at the mature stage of the intra‐erythrocytic phase. Of note, 
recombinant PfPM4 hydrolyzes spectrin at pH 6.6 in a similar pattern as recombinant 
PfPM2 does [97]. Further, a 37‐kDa aspartic proteinase purified from the rodent malaria 
parasite P. berghei enables hydrolysis of spectrin and protein 4.1 from human erythro‐
cytes at physiological pH [98]. Based on these pieces of evidence, it is likely that the FV 
PM‐mediated host cell remodeling commonly occurs in the intra‐erythrocytic phase of 
Plasmodium spp. (Figure 3).
4.3. Ookinetes midgut invasion and oocyst development
PM4 (PgPM4) from the avian malaria parasite P. gallinaceum is involved in ookinete invasion 
of mosquito midguts and oocyst development during the sporogonic phase (Figure 3) [99]. 
In its mosquito host, P. gallinaceum expresses PgPM4 in zygotes and ookinetes. In ookine‐
tes, PgPM4 is located at the apical membrane surface as well as in micronemes, an organelle 
of apicomplexan parasites involving in protein secretion. Monoclonal antibodies directed 
against PgPM4 block oocyst development, but have no effects on ookinete formation. PgPM4, 
together with chitinase and other enzymes, is speculated to hydrolyze peritrophic matrix pro‐
teins during ookinetes’ midgut invasion, a critical step for parasite development. Questions 
remain elusive, such as how the expression of PgPM4 and its orthologs is spatio‐temporally 
regulated in the life cycle of malaria parasites, whether PM4 orthologs from other Plasmodium 
spp. play a similar role, what the natural substrates of PgPM4 are, and how PgPM4 recognizes 
and cleaves its substrates.
Of particular note, antibodies directed against the catalytic domain of either PfPM7 or PfPM10 
decrease the prevalence of P. falciparum invasion of the mosquito and reduce the intensity of 
developed oocysts [69], indicating the involvement of mature PfPM7 or PfPM10 in parasite 
development during the sporogonic phase as well.
4.4. Host-targeted protein export
In the intra‐erythrocytic phase, malaria parasites express and export hundreds of proteins, 
collectively named the “exportome,” to infected red blood cells in order to acquire nutrients, 
to remodel the host cell, to avoid host immune detection, and to promote virulence [100–102]. 
A portion of the exportome shares at the N‐terminus a pentameric sequence motif of RxLxE/
Q/D (x represents any natural amino acid), known as the Plasmodium export element (PEXEL) 
[101] or the vacuolar transport signal [100]. A cleavage of the PEXEL motif at the C‐terminus 
of leucine triggers the PEXEL‐containing proteins to traverse the PPM and PVM, and subse‐
quently reach the host cell [103]. PM5 catalyzes this reaction in the ER following the transla‐
tion of PEXEL‐containing proteins (Figure 3) [64, 104].
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PM5‐mediated PEXEL cleavage is proved to be essential to not only protein export but 
also parasite survival in that episomal expression of a catalytically inactive PM5 mutant 
decreases the level of proteins exported to host cells and slows down the parasite growth 
rate [64]. Interestingly, when the PEXEL motif of the P. falciparum erythrocyte membrane 
protein 3 (PfEMP3) is engineered such that a signal peptidase, but not PM5, is able to con‐
duct the cleavage, the resulting protein is transported to the parasitophorous vacuole rather 
than the cytoplasm of host cell, even if it has the same acetylated‐xQ sequence retaining 
at the N‐terminus as the PM5‐cleaved mature PfEMP3 does [104]. Meanwhile, when pro‐
teins are engineered to alter the prime side sequence of the PEXEL motif, the processed 
mature proteins fail to export to host erythrocytes even if PM5 performs the cleavage [105]. 
These findings highlight the importance of both PM5's involvement in the cleavage and the 
exposure of appropriate N‐terminal sequence of the mature protein in host‐targeted protein 
export. Detailed mechanisms related to how PM5‐mediated PEXEL cleavage contributes to 
host‐targeted protein export, and other potential roles of PM5 in the protein export event 
remain elusive.
Of particular note, the host‐targeted malaria protein export is not restricted in the intra‐eryth‐
rocytic phase but occurs over the course of the parasite life cycle [66, 106, 107], which coin‐
cides with the spatio‐temporal expression pattern of PM5 [44, 65, 66]. It is thus conceivable 
that PM5 is also involved in protein export at other stages of the parasite life cycle, though no 
supporting evidence has been reported yet.
4.5. Other functions
Recent studies from Spaccapelo and colleagues showed the role of PM4 (PbPM4) from the 
rodent malaria parasite P. berghei in maintaining virulence and suppressing innate immune 
responses of parasite‐infected mice (Figure 3) [108, 109]. Supporting evidence comes from 
the observations that (1) the parasite with pbpm4 genetically ablated (Δpbpm4) fails to elicit 
experimental cerebral malaria (ECM) in the ECM‐susceptible mice; (2) the Δpbpm4 is unable 
to kill the ECM‐resistant mice as the parent strain does, but is cleared from blood after a 
three‐week infection; and (3) after a single infection of naïve hosts by the Δpbpm4, these 
convalescent mice gain immune protection from a later parent strain infection. The mecha‐
nism by which PbPM4 contributes to parasite virulence warrants further investigation.
In another study [110], recombinant PbPM4 expressed and purified from E. coli was injected 
intraperitoneally (i.p.) in mice, together with the adjuvant saponin; sera obtained from the 
immunized mice contain antibodies that can recognize the cultured P. berghei strain from 
which the immunogen‐encoding sequence originates. In addition, i.p. injecting erythorcytes 
infected by this P. berghei strain into PbPM4‐immunized mice boosts their production of the 
parasite‐recognizing antibodies in vivo. Interestingly, three of five PbPM4‐immunized mice 
show resistance to P. berghei infection with the parasitaemia percentage reduced by an order 
of magnitude compared to naïve mice. These findings suggest that PMs are able to serve both 
as drug targets and as immunogens for malaria control (Figure 3). Though whether PM4 
homologs residing in the host‐infecting parasites are able to elicit a similar immune response 
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as purified recombinant forms is not yet clear, their potential immunogenic role in malaria 
prevention and treatment merits further investigation.
5. Enzymatic characterization
5.1. Food vacuole plasmepsins
5.1.1. Plasmodium falciparum plasmepsin 1
The naturally‐occurring PfPM1 runs as a 37‐kDa monomeric protein in SEC, indicative of its 
mature form [47, 83]. Purified naturally‐occurring PfPM1 hydrolyzes native hemoglobin at 
α33‐34 at an optimal pH 5.0 [83], within the pH range of the FV [111, 112]. This reaction is fully 
inhibited by pepstatin, a typical aspartic proteinase inhibitor, at nanomolar magnitude, but 
little by serine, cysteine or metallo‐proteinase inhibitors in the millimolar range [83].
PfPM1 of the recombinant form was expressed in E. coli. To obtain catalytically active mature 
enzyme, two technical obstacles were overcome: first, to avoid the potential toxicity the puta‐
tive transmembrane motif exerts to E. coli, a truncated construct lacking the N‐terminal half of 
the pro‐segment was used [113]; second, to confer the auto‐maturation capability on the trun‐
cated zymogen, this PfPM1 construct was further engineered by introducing a self‐cleavage 
site in the pro‐segment [51, 52], by retaining a longer pro‐segment [114], or by co‐expressing 
with thioredoxin in one open reading frame [115]. These engineered PfPM1s conduct auto‐
maturation at pH 4.0–5.5; however, the resulting mature enzyme retains a 7‐ or 12‐amino‐
acid pro‐segment [51, 52, 115]. Furthermore, the PfPM1 produced by auto‐maturation in vitro 




) in cleaving hemoglobin‐derived sub‐
strates than the naturally‐occurring, mainly due to lower k
cat
 values [52, 115, 116]. These find‐
ings suggest that the presence of a short piece of pro‐segment in the in vitro auto‐matured 
PfPM1 inhibits the enzyme activity and that the inhibition may occur in a different way than 
that it directly occupies the active site, like the case of pepsinogen and progastricsin [117–120]. 
In support of this, a crystal structure of the highly homologous PfPM2 zymogen demonstrates 
that the pro‐segment blocks enzyme activity by harnessing the C‐terminal domain away from 
the N‐terminal half to prevent the cooperative action of the catalytic dyad [120, 121].
The subsite specificity of PfPM1 at S3 – S3' was analyzed using combinatorial chemistry‐
based peptide libraries [52]. In this study, the degree of accommodation of each of the 19 
amino acids (i.e., norleucine and the 20 natural amino acids omitting methionine and cyste‐
ine) at each of the six subsites was quantitatively assessed. Ultimately, the peptide sequence 
comprising the best accommodated amino acid at each investigated position, in the order 
of P3–P3', is FSF*LQF (* represents the scissor bond). By comparing data to those obtained 
using the same method from analyzing human cathepsin D (hcatD), the most homologous 
human enzyme to FV PMs, a peptide sequence was deduced comprising at each position an 
amino acid that is well fit in PfPM1, but better recognized by PfPM1 than by hcatD. A pep‐
tidomimetic inhibitor (KPFSLΨLQF, where Ψ = –CH2–NH–), converted from such peptide sequence by reducing the scissor bond to the non‐cleavable methyleneamino (–CH2–NH–), 
Natural Remedies in the Fight Against Parasites194
exhibit an inhibition of PfPM1 with the dissociation constant (K
i
) in nanomolar magnitude 
and a >5‐fold selectivity for PfPM1 over hcatD. In another study using a random decamer 
peptide library, Siripurkpong and colleagues showed that PfPM1 prefers accommodating 
leucine and serine at S1' and S2', respectively [122]. While the two studies agreed on the S1' 
subsite specificity, the discrepancy at S2' may arise from difference in enzyme preparation, 
peptide library composition, or catalytic conditions.
5.1.2. Plasmodium falciparum plasmepsin 2
The naturally‐occurring PfPM2 is purified as a 36‐kDa mature enzyme, separated from PfPM1 
by elution at a lower salt concentration [47]. As discussed in Section 3.1, the naturally‐occur‐
ring PfPM2 cleaves native hemoglobin at α33‐34 less efficiently than PfPM1 [47]; however, it 
digests acid‐denatured globin 3‐fold more efficiently than PfPM1 [113]. Similar to the natu‐
rally‐occurring PfPM1, PfPM2 is tightly inhibited by pepstatin with the K
i
 in sub‐nanomolar 
magnitude [113, 116].
Unlike the case of PfPM1, a recombinantly expressed truncated PfPM2 zymogen lacking the 
putative transmembrane motif fully converts itself to mature enzyme in acidic conditions [53]. 
PfPM2 generated from in vitro auto‐maturation retains a 2‐ or 12‐amino‐acid pro‐segment; 
though, the in vitro auto‐matured enzyme and its naturally‐occurring counterpart shares simi‐
lar kinetic efficiencies in digesting hemoglobin‐derived substrates and inhibition by peptido‐
mimetic compounds [113, 116]. Interestingly, PfPM2 can adopt the proper conformation from 
in vitro protein refolding such robustly that deleting part of (e.g. Δ112p–121p) or the entire 
pro‐segment costs no loss of its catalytic activity [123, 124].
Beyer and colleagues studied the subsite specificity of PfPM2 at S3 – S3' using the combinato‐
rial chemistry‐based peptide libraries discussed in Section 4.1.1 [125]. PfPM2 prefers accom‐
modating bulky hydrophobic residues (e.g., norleucine, leucine, isoleucine and phenylalanine) 
in all studied subsites except for the S2', where glutamine is the most favored. The peptide 
sequence comprising the most favored amino acid at each position, in the order of P3 – P3', 
is nLInL*LQI (nL = norleucine). A peptidomimetic inhibitor (KPnLSnLΨLQI) designed using 
the same approach described above exhibits an inhibition of PfPM2 with the K
i
 at nanomolar 
magnitude and a >15‐fold selectivity for PfPM2 over hcatD. In two earlier studies, the catalytic 
activity of PfPM2 was assessed in cleaving five sets of chromogenic octapeptides; peptide 
substrates within a particular set differ in amino acids substituted in one of the P4, P3, P2, P2' 
and P3' positions [126, 127]. The results showed that peptides with large hydrophobic amino 





values, consistent with the findings from the combinatorial peptide library study. In addi‐
tion, Siripurkpong and colleagues reported that PfPM2 digests a library of random decameric 
peptides most efficiently when leucine is placed in the P1' position and that the enzyme has 
comparable kinetic efficiencies when residues of different properties (e.g., serine, methionine, 
alanine and glutamine) are placed in the P2' position [122], again consistent with the previous 
findings. Of note, an N‐terminal extension of peptide substrates to P6 enhances the kinetic 
efficiency of PfPM2, and yet C‐terminally extended peptides manifest no such effect [124]. The 
possible presence of a similar effect in other PM homologs is unclear yet.
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5.1.3. Plasmodium falciparum histo‐aspartic proteinase
HAP is a PM with the catalytic aspartic acid of the N‐terminus replaced by a histidine. 
Naturally‐occurring PfHAP, purified as a monomeric mature enzyme of ~37 kDa, cleaves 
hemoglobin‐derived substrates at an optimal pH 5.7 [48]. PfHAP shows nearly no cleavage 
of native hemoglobin, but is able to digest acid‐denatured globin and to hydrolyze α33‐34 
in hemoglobin‐derived peptide substrates [48]. Nonetheless, PfHAP cleaves α33‐34 20‐fold 
less efficiently than PfPM1 and PfPM2 [48, 113]. The naturally‐occurring PfHAP can be fully 
inhibited by isovaleryl‐pepstatin (pepstatin A) at 1 μM and by the serine proteinase inhibitor 
phenylmethylsulfonyl fluoride (PMSF) at 1 mM [48].
Catalytically active PfHAP of the recombinant form was obtained using a similar strategy as the 
one applied to recombinant PfPM1 [128, 129]. The in vitro auto‐matured PfHAP retains 4 pro‐
segment residues [128]. It exhibits an optimal catalytic activity at pH 5.2 and lowers kinetic effi‐
ciencies in cleaving hemoglobin‐derived peptides than its naturally‐occurring counterpart [128]. 
In addition, though pepstatin A at 1 μM completely inactivate the enzyme, PMSF at 1 mM inhib‐
its enzyme activity by only 25% [128]. The apparent differences in enzymatic features between 
the naturally‐occurring PfHAP and the in vitro auto‐matured may be attributable to improper 
folding of the recombinant protein [128] and/or the inhibition effects of the pro‐segment [120].
A key question remains elusive is whether PfHAP functions as an aspartic or a serine protein‐
ase. Based on results from computational modeling, some view PfHAP as a serine proteinase 
with a catalytic triad of H34, S37 and D214 [130], and others consider PfHAP an atypical aspar‐
tic proteinase with D214 performing catalysis and H34 stabilizing the intermediate enzyme 
species [131]. By conducting alanine mutation of these residues related to catalysis, Parr and 
colleagues showed that D214A renders PfHAP incapable of auto‐maturation, whereas H34A 
and S37A do not affect auto‐maturation, but lead to a lower kinetic efficiency in cleaving pep‐
tide substrates [132]. These findings support the role of D214 in enzyme catalysis, indicating 
that PfHAP is an atypical aspartic proteinase.
5.1.4. Plasmepsin 4 orthologs
To the author's knowledge, no literatures have thus far reported the characteristics of nat‐
urally‐occurring PfPM4. The recombinantly expressed PfPM4 zymogen lacking the puta‐
tive transmembrane motif conducts auto‐maturation under acidic conditions, resulting in a 
mature form retaining 12 pro‐segment residues [48]. This mature PfPM4 cleaves hemoglobin‐
derived peptides at an optimal pH 5.4 [48]. PfPM4 digests native hemoglobin less efficiently 
than PfPM1 and PfPM2 and prefers cleaving acid‐denatured globin [48]. Similar to PfPM1 and 
PfPM2, but unlike PfHAP, PfPM4 is fully inhibited by pepstatin A at sub‐nanomolar magni‐
tude, but not by inhibitors of other types of proteinases [48, 54].
Recombinant PM4s from the other three human malaria parasites and the rodent malarial para‐
site P. berghei were similarly produced and activated [54, 126, 133]. The subsite specificity at S3 – 
S3' of the five PM4 orthologs (i.e., PfPM4, PoPM4, PvPM4, PmPM4 and PbPM4) was investigated 
using combinatorial peptide libraries [125, 133]. All five PM4s unanimously prefer accommodat‐
ing phenylalanine or tyrosine at S1 and S1', except that PbPM4 accommodates norleucine best 
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at S1'. At S3, bulky hydrophobic amino acids, such as leucine, norleucine and phenylalanine, are 
preferred by all five enzymes. At S3', the acceptance of amino acids by the four human PM4s is 
broad with isoleucine accommodated best, whereas PbPM4  accommodates aromatic phenylala‐
nine and tryptophan best. For S2 and S2', all five PM4s seem to tolerate amino acids of different 
properties. Glutamic acid, serine and isoleucine are the most favored at S2; while for glutamine, 
isoleucine, glutamic acid and arginine, when accommodated in S2', each leads to a considerable 
peptide cleavage. The peptide sequence comprising the most favored residue by each subsite, 
in the order of P3 – P3', is IQF*YIL for PfPM4, is FEF*YFI for PoPM4, is LEF*FII for PvPM4, is 
FEF*FII for PmPM4, and is FEF*nLSW for PbPM4. Peptidomimetic inhibitors were designed 
using the same approach described in Section 4.1.1: KPVEFΨRQT for PfPM4, KPLEFΨFRV for 
PoPM4, KPLEFΨYRV for PvPM4, KPFELΨAWT for PmPM4, and KPYEFΨRQF for PbPM4. 
These compounds unanimously exhibit a selective inhibition of their respective PM4s over 
hcatD, and inhibit their respective PM4s with the K
i
 values at sub‐nanomolar to nanomolar 
magnitude, except for the one designed for PmPM4, which inhibits PmPM4 with the K
i
 at micro‐
molar magnitude. Such a poor inhibition may be due to the incorporation in the P1' position of 
an alanine that is poorly recognized by PmPM4, indicating the key role of the P1' amino acid in 
determining the enzyme‐ligand interaction. In another two studies, the subsite specificity of the 
four human PM4s was analyzed at S3, S2, S2' and S3' using chromogenic octapeptides [54, 126]. 
The results showed that (1) hydrophobic amino acids (e.g., phenylalanine and isoleucine) are 
more favored at P3 than smaller hydrophobic, polar and charged amino acids, (2) hydrophobic 
amino acids are favored at P2, and (3) amino acids of different properties at P2' and P3' are well 
tolerated. These findings are consistent with the data obtained from the combinatorial peptide 
library study.
5.2. Non-food vacuole plasmepsins
Thus far, enzymatic characterization of non‐FV PMs has been focused on the PM5 ortho‐
logs. PM5 (PfPM5) immunopurified from cultured P. falciparum cleaves PEXEL (RxLxQ/
E/D)‐containing substrates at the C‐terminus of leucine at pH 5–7 [64], resembling the pH 
of the mammalian ER [134]. The PEXEL‐cleaving activity of PfPM5 is partially inhibited 
by pepstatin A and HIV‐1 PIs (i.e., lopinavir, nelfinavir, ritonavir and saquinavir) with the 
IC50 values in the high micromolar range [64, 104]. The presence of P3 R and P1 L is key 
to PfPM5‐catalyzed PEXEL cleavage in that mutations in these two positions (e.g., P3 R‐
to‐A or K and P1 L‐to‐A or I) unanimously inhibit the cleavage, and abolish the export of 
PEXEL‐containing proteins to host erythrocytes; amino acids in the prime side positions 
also influence the efficiency of PEXEL cleavage and subsequent protein export [104, 105, 
135]. PfPM5 also digests non‐canonical PEXEL motifs (e.g., RxLxxE) at the C‐terminus of 
P1 L, which in turn, triggers host‐targeted protein export [105]. Likewise, this PfPM5‐cata‐
lyzed non‐canonical PEXEL cleavage and subsequent protein export are blocked by a P3 
R‐to‐A mutation [105]. Of note, though deleting neither the P1' nor the P2' amino acid affects 
enzyme cleavage, protein export efficiency is reduced by these prime side mutations [105]. 
Taken together, these findings highlight the essential role of P3 R and P1 L in modulating 
PfPM5‐mediated PEXEL cleavage and the importance of the prime side peptide sequence in 
directing host‐targeted protein export.
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Two constructs of PfPM5 encoding a truncated zymogen (amino acids 37–521) and a mature 
enzyme (amino acids 84–521) have been recombinantly expressed in E. coli [136, 137]. 
Following in vitro protein refolding, both the zymogen and the mature enzyme exhibit cat‐
alytic activity in cleaving PEXEL‐containing peptides at an optimal pH 6.0–6.5 [136, 137]. 
Indeed, the pro‐segment of PfPM5 was shown to be non‐essential for guiding the proper fold‐
ing of protein [137, 138]. Subsite specificity analysis of the recombinant mature PfPM5 on a 
peptide series of RxLxE at P2 and P1' showed that when the polar serine is placed at P1', the 
hydrophobic isoleucine is more favored at P2 than the charged glutamic acid and lysine; and 
vice versa, when isoleucine is placed at P2, serine is better accommodated at S1' than glutamic 
acid and the hydrophobic valine [136]. Recombinant PfPM5, like the parasite‐expressed, can 
only be partially (<50%) inhibited by pepstatin A, nelfinavir or PMSF at 100 mM; however, 
its catalytic activity is almost fully blocked by Cu2+ or Hg2+ at the sub‐micromolar level [137]. 
Furthermore, the zymogen and mature form of PM5 (PvPM5‐Thai) from P. vivax Thailand 









PfPM1 Intra‐erythrocytic phase; 
merizoites; gametocytes
FV, TV 5.0 Hb FSF*L(Q/S)F <1 nM (K
i
)
PfPM2 Intra‐erythrocytic phase; 
merizoites; gametocytes; 
oocysts; sporozoites






PfHAP Intra‐erythrocytic phase; 
merizoites; gametocytes; 
sporozoites
FV, TV 5.7 Hb n.d. 1 μM (fully 
inhibition)
PfPM4 Intra‐erythrocytic phase; 
merizoites; gametocytes; 
oocysts; sporozoites






PvPM4 Intra‐erythrocytic phase FV, TV 4.5 Hbc LEF*FII <1 nM (K
i
)
PoPM4 n.d. FV, TV 4.5 Hbc FEF*YFI <1 nM (K
i
)
PmPM4 n.d. FV, TV 4.5 Hbc FEF*FII <1 nM (K
i
)


















aThis column shows the subcellular locations of catalytically active, mature plasmepsins.
bThis column shows the optimal catalytic pH; for PfPM2 and PfPM4, digestion of host cytoskeletal proteins is carried 
out at near neutral pH.
cDigestion of these natural substrates were performed in vitro using recombinant plasmepsins.
dThis column shows the best amino acids accommodated at subsites in the order of P3 – P3′; * represents scissile bond 
between P1 and P1′; x represents any natural amino acid; nL = norleucine.
Table 2. Enzymatic properties of plasmepsins.
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isolates were recombinantly expressed; the purified PvPM5‐Thai exhibits similar enzymatic 
features as the recombinant PfPM5 does [139].
The enzymatic properties of PMs discussed in this section are summarized in Table 2.
6. Plasmepsin-targeted antimalarial drug development
6.1. Evaluation of food vacuole plasmepsins as antimalarial drug targets
The establishment of the role of FV PMs in hemoglobin processing raised the question whether 
FV PMs can be targets of novel antimalarial drugs. Peptidomimetic compounds developed in 
the early stage (e.g., pepstatin A, SC‐50083, Ro40‐4388, and HIV‐1 PIs) bind FV PMs tightly 
and block growth of cultured parasites [46, 51, 140, 141], suggesting that inhibition of FV PMs 
is a promising antimalarial strategy. Numerous types of FV PM‐targeted compounds, syn‐
thetic or isolated from natural sources, have been assessed for the past two and a half decades 
based on criteria involving binding affinity and selectivity, inhibition potency to cultured 
parasite growth, and cytotoxicity to mammalian cell culture (for reviews, see for example 
[142, 143]). For example, certain hydroxyethylamine derivatives inhibit PfPM1, PfPM2 and 
PfPM4 in nanomolar magnitude, exhibit a >30‐fold binding selectivity over hcatD, and dis‐
rupt growth of cultured P. falciparum with IC50s in the low micromolar range [144, 145]. In 
a series of studies, several allophenylnorstatine‐based compounds were found to inhibit all 
four FV PfPMs in nanomolar magnitude, to block parasite growth with IC50s in the low micro‐
molar range, and to have the TD50s (cytotoxicity) in high micromolar magnitude to rat skel‐
etal myoblasts [146–148]. In addition, clinically used HIV‐1 PIs exhibit antimalarial activity on 
parasites in both the exo‐erythrocytic and the intra‐erythrocytic phases in the sub‐micromolar 
to low micromolar range [149–151], inhibit PfPM2 and PfPM4 at low micromolar magnitude, 
and have a >10‐fold selectivity over hcatD [141]. Interestingly, using affinity binding probes 
coupled to a FV PM inhibitor library, a hydroxyethyl‐based inhibitor was identified that 
inhibits all four FV PfPMs and the growth of cultured P. falciparum with IC50 at ~1 μM [152].
To assess whether FV PMs are appropriate drug targets, pfpm4, 1, 2 and pfhap were knocked 
out individually (i.e., Δpfpm4, Δpfpm1, Δpfpm2 and Δpfhap), in combination (e.g., Δpfpm4/1 and 
Δpfpm1/2/hap), or together as a whole (i.e., Δpfpm4/1/2/hap). Genetic ablation of any particu‐
lar gene alters neither the mRNA transcription nor the protein expression of the other three 
paralogs over the course of the intra‐erythrocytic phase [153]. For hemoglobin metabolism, 
the Δpfpm4 strain, but not the Δpfpm1, Δpfpm2 or Δpfhap, shows a reduction in hemozoin 
accumulation in the FV compared to the parent line [154, 155]. Of note, genetic disruption of 
PM expression does affect the rate of parasite replication in that the Δpfpm4, Δpfpm1, Δpfpm2, 
Δpfpm4/1 and Δpfpm4/1/2/hap strains all exhibit a reduced growth rate in amino‐acid‐rich 
media compared to the parent line, and that when cultured in amino‐acid‐limited media, the 
Δpfhap strain also demonstrates a slower growth rate [153–157]. As for cell and subcellular 
organelle morphology, though no morphological abnormalities are apparent in the Δpfpm1 
and Δpfhap strains, a portion of the Δpfpm2 shows enlarged mitochondria, and a portion of the 
Δpfpm4 exhibits a notable accumulation of electron‐dense, single‐membrane vesicles in the FV 
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[154, 156]; in addition, ceroid‐like multilamellar bodies, and electron‐dense, single‐membrane 
vesicles are accumulated in the FV of the Δpfpm4/1/2/hap strain [155]. Taken together, genetic 
ablation of pfpms is not lethal to the parasite in cultured conditions despite apparent metabolic 
and pathological abnormalities, thus it seems that FV PMs may be dispensable for parasite 
survival; however, one cannot overlook the potential contribution of PbPM4 to the virulence 
of the parasite in infected mice (see discussion in Section 4.5). Understanding the pathological 
role of FV PMs in both cell‐based and animal models may lead to a better assessment of the 
feasibility of PM‐targeted drug development.
To better understand the relationship between enzyme inhibition and anti‐parasitic activity, 
the effects of known FV PM inhibitors on the growth of PM‐knockout parasites were inves‐
tigated. When pepstatin A was administered to cultured parasite in the intra‐erythrocytic 
phase, growth of the Δpfpm1, Δpfpm2, Δpfhap and Δpfpm4/1 strains is even slightly less sensi‐
tive to the compound than that of the parent line, and yet growth of the FP‐2‐knockout strain 
is at least one order of magnitude more sensitive to pepstatin A [156, 157]. These findings 
indicate that the parasite may turn to other proteinases to maintain normal function when 
the activities of FV PMs are blocked. The effects of HIV‐1 PIs on in vitro PM inhibition and 
blockage of parasite growth have been well established [141, 158]. However, the Δpfpm1/2/hap 
and Δpfpm4/1/2/hap strains share a comparable sensitivity to five HIV‐1 PIs (i.e., atazanavir, 
lopinavir, indinavir, ritonavir and saquinavir) with the parent line [155], indicating that FV 
PMs may not be the target of these inhibitors in the parasite [141]. Such off‐target effects are 
rather common among developed PM inhibitors of distinct classes (e.g., C2‐symmetric 1,2‐dihydroxyethylenes [159], hydroxylethylamine transition‐state isosteres [145] and amidine‐
containing diphenylureas [160]). The authentic targets of these inhibitors in the parasite have 
been under investigation [161].
Despite that FV PMs are not critical to parasite survival at the blood stage and that certain FV PM 
inhibitors exhibit their anti‐parasitic activities with an off‐target effect, it is still early to negate 
FV PM‐targeted drug design given our limited understanding of their functions and character‐
istics. The continuously identified novel functions of FV PMs plus their broad spatio‐temporal 
expression pattern over the course of the parasite life cycle are worthy of further investigation.
6.2. Developing novel antimalarial drugs targeting non-food vacuole plasmepsins
PM5 has been considered an ideal target for novel antimalarial drug design based on a series 
of findings: first, ablation of the gene encoding PM5 is lethal to cultured P. berghei [104], so 
is mutation of a catalytic aspartic acid of PM5 to cultured P. falciparum [64]; second, PM5 is 
evolutionarily conserved among Plasmodium spp. with no identified gene replication or func‐
tional redundancy [44]; third, PM5 shares a low amino acid sequence identity with human 
aspartic proteinases (e.g., 26% with mature hcatD, and 18% with mature human β‐secretase 
1 (hBACE‐1)); and fourth, the expression profile of PM5 spans the entire life cycle of malaria 
parasites [44, 65, 66].
Two basic components were incorporated in the initial design of PM5 inhibitors: a PEXEL 
sequence, which provides a moderate fit of compounds to the active site of the enzyme, and 
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a transition‐state peptidomimetic moiety, which gives rise to a tight interaction with the cata‐
lytic residues of proteinases. WEHI‐916, a statine‐based compound mimicking the non‐prime‐
side RVL motif of the PEXEL, shows a strong inhibition (IC50 = ~20 nM) of PfPM5 and PvPM5, 
a much weaker inhibition of hcatD (IC50 = 25 μM), and a negligible inhibition of hBACE‐1 
(IC50>100 μM) [162, 163]. Administration of WEHI‐916 to cultured P. falciparum blocks the 
PEXEL cleavage in a dose‐dependent manner, and impairs protein export to host erythrocytes 
[162]. Of particular interest, conditioned knockdown of pfpm5 enhances WEHI‐916‐medi‐
ated inhibition of PEXEL cleavage and the sensitivity of parasite growth to this compound; 
whereas overexpression of PfPM5 weakens the anti‐parasitic potency of WEHI‐916 [162]. 
These findings confirm that PM5 is the target of WEHI‐916 in the parasite. Though, WHEI‐916 
has only a moderate potency (EC50 = 2.5 μM to the strain 3D7) in killing cultured P. falciparum, 
which may be attributed to its poor membrane permeability [162, 163]. To enhance the anti‐
parasitic potency of WEHI‐916 while retaining its strong binding to PM5, the highly polar P3 
arginine in WEHI‐916 was modified to its isostere L‐canavanine, and the N‐terminal sulfon‐
amide was replaced by a carbamate [164, 165]. The resulting compound WEHI‐842 inhibits 
PfPM5 and PvPM5 more tightly (IC50 = 0.2–0.4 nM), and blocks the PEXEL cleavage and pro‐
tein export more potently than WEHI‐916 [165]. Importantly, WEHI‐842 kills the chloroquine‐
sensitive 3D7 strain and multiple chloroquine‐resistant P. falciparum strains with a potency 
(EC50 = 0.4 μM) one order of magnitude higher than that of WEHI‐916, and yet it exhibits a 
low cytotoxicity against human cells (TD50>50 μM) [165]. Taken together, WEHI‐842 repre‐
sents a promising lead for developing PM5‐targeted antimalarial drugs.
Our limited knowledge on PMs 6–10 makes it difficult to assess the necessity and impor‐
tance of developing drugs targeting these enzymes. However, the detection of these PMs in 
multiple stages of the parasite life cycle suggests that their role in malaria pathogenesis is 
non‐trivial. For future PM‐targeted drug development, the functions and characteristics of 
PMs 6‐10 warrant further study.
7. Concluding remarks
Malaria, one of the deadliest infectious diseases in history, still poses a serious socio‐economic 
problem at present. Malaria control has been effectively undertaken from multiple perspectives, 
including drug‐based disease prevention and treatment, intervention of malaria transmission 
by the mosquito vector, and usage of vaccine against malaria parasites. Though, the emer‐
gence and quick spread of drug‐resistant parasite strains urges us to identify new antimalarial 
drug targets. The subject of this review has focused on the aspartic proteinase PM family, the 
molecular entities deemed novel and promising targets of next‐generation antimalarial drugs.
Discussed here is our understanding of the PM family members on their biosynthesis, bio‐
logical functions and characteristics for the past two and a half decades. Seven groups of PMs 
have thus far been identified from genome comparison of a series of Plasmodium spp. infecting 
rodents, birds, humans and non‐human primates. These PMs, unique in enzymatic feature and 
spatio‐temporal expression pattern, play multifaceted roles in the pathogenicity of the malaria 
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parasite. Due to the seemingly dispensable role of FV PMs in parasite growth and survival, the 
focus of PM‐targeted drug development is shifting towards non‐FV PMs. Selective inhibitors 
of PM5 have been developed and shown strong inhibition potency to parasite growth.
On the other hand, our knowledge on PMs is still quite limited and much needs to be clari‐
fied and explored in the future studies. For example, what is the biological meaning of the 
presence of four FV PM paralogs in P. falciparum? What do the FV PM inhibitors authenti‐
cally target to exert their anti‐parasitic activity? What are other possible roles of PM5 than 
host‐targeted protein export? What are the functions of PMs 6‐10, and can these enzymes be 
antimalarial drug targets? What is the likelihood that PMs are used as immunogens in active 
immunization and that antibodies directed against PMs are used in passive immunization 
to protect hosts from malaria parasite infection? Successful PM‐targeted drug development 
replies on a comprehensive understanding of this enzyme family.
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